Mode
Text Size
Log in / Sign up
N/A N=96 Randomized Treatment

Recurrent Pterygium Surgery Using Mitomycin C With Limbal Conjunctival or Amniotic Membrane

Recurrent Pterygium

Enrolled (actual)
96
Serious AEs
0.0%
Results posted
Mar 2015
Primary outcome: Primary: Recurrence — 46; 34; 0; 3 eyes — p=<0.05

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
MMC (Procedure); LCAG (Procedure); AMG (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Shiyou Zhou
Primary completion
Jun 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Recurrence
46; 34; 0; 3; 0; 2 <0.05 sig
SECONDARY
Complications
9; 8 <0.05 sig
SECONDARY
Healing Time of Corneal Epithelial Defect
2.78; 3.25 0.05
SECONDARY
Eye Movement Amplitude (EMA)
6.67; 6.79; 8.35; 7.85; 1.67; 1.06 <0.05 sig
SECONDARY
Postoperative Conjunctival Inflammation
21; 14; 17; 14; 9; 13 <0.05 sig

Summary

To compare the outcomes of limbal conjunctival autograft (LCAG) versus amniotic membrane graft (AMG) when combined with intraoperative 0.02% mitomycin C (MMC) after pterygium removal in patients with recurrent pterygium.

Eligibility Criteria

Inclusion Criteria

  • The patients had one or two eye(s) with unilateral recurrent pterygium.
  • Recurrent pterygium:be defined as of fibrovascular tissue onto the cornea for any distance in the position of a previous pterygium.
  • Willingness to participate in research project and to attend research time.

Exclusion Criteria

  • Poor general health.
  • Pregnant or lactating women.
  • Patients with collagen vascular diseases or other autoimmune diseases.
  • Patients with any evidence of stem cell deficiency.
  • Patients with glaucoma who might require future filtering surgery.
  • Patients with ocular infection.
  • Patients with an allergy to mitomycin C, tobramycin or dexamethasone.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01319721). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search